CELL LINE DEVELOPMENT
Speed, Stability, & High Yield
At Altruist Biologics, we understand the complexities and challenges that companies face when developing biologics. From IND to BLA submission, our comprehensive cell line development (CLD) services are designed to streamline every step of your journey.
Performance Snapshot
Speed
10 weeks from DNA to Primary Cell Bank generation
Productivity
13g/L mAb titer
Stability
99% stable lead clones
Our Facilities
Facilities Built for the Full CDMO Process
- High-Throughput Equipment
- Cutting-edge technologies
- Advantages of transposon-based expression construction
- Pool expression: 1.2~1.5-fold increase (STI-pool >= RTI-pool)
- Cell line development: Achieved 2.5 months timeline from DNA to PCB
- Clone expression levels: STI-Clone = RTI-Clone
- STI: Semi-targeted Transgene Integration (Transposon-mediated integration)
- RTI: Random Transgene Integration
End-to-End Development Workflow
We offer comprehensive mammalian cell line development services, including screening for high-yield, high-quality, and stable monoclonal cell lines, establishment of primary cell banks, and establishment and testing of master and working cell banks under GMP conditions.
High-Product Yield
To date, we have constructed hundreds of stable cell lines for clinical and commercial production.
- Routinely reach mAb titers of 5-10 g/L and headline titers of up to 13 g/L in fed-batch mode
- Express bispecific, tri-specific and Fc-fusion proteins at titers comparable to mAbs (up to 13 g/L)
Reliable Host Cell Lines: We utilize well-proven host cell lines, including our in-house CHO-K1 (AltruCHOice), CHO-K1, CHO-S and CHO-K1 GS-KO.
Contact
Seamless Gene to GMP Manufacturing
With centralized gene-to-GMP capabilities and proven expertise, learn how Altruist provides seamless, end-to-end support for your path to market.
Send a Message
